Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Collaboration and license revenue		$ 30,041	$ 30,374	$ 2,751
Other revenue			732
Total revenue		30,041	31,106	2,751
Operating expenses:
Research and development (includes related party of $42,768, $21,723 and $9,471 for the years ended December 31, 2015, 2014 and 2013, respectively)		213,062	78,224	31,279
General and administrative (includes related party of $559, $597 and $18 for the years ended December 31, 2015, 2014 and 2013, respectively)		36,046	17,564	7,465
Total operating expenses		249,108	95,788	38,744
Loss from operations		(219,067)	(64,682)	(35,993)
Interest expense (includes related party of $2,687 and $4,026 for the years ended December 31, 2014 and 2013, respectively)		(33)	(3,900)	(5,293)
Other expense, net		(4,838)	(18,595)	(12,349)
Net loss		(223,938)	(87,177)	(53,635)
Net loss attributable to non-controlling interest		678	44
Net loss attributable to Coherus		$ (223,260)	$ (87,133)	$ (53,635)
Net loss per share attributable to Coherus, basic and diluted		$ (6.01)	$ (10.64)	$ (16.10)
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted		37,122,008	8,186,529	3,332,020
Baxalta License Agreement
Revenue:
Collaboration and license revenue		$ 27,802	$ 28,481	$ 726
Daiichi Sankyo - Related Party
Revenue:
Collaboration and license revenue	[1]	$ 2,239	$ 1,893	$ 2,025

[1] Represents revenue from Daiichi Sankyo through November 12, 2014 as a related party, a holder of more than 10% of our common stock until the closing of our initial public offering (“IPO”).